de Micheli SA , Pastelín HG

Language: Spanish
References: 54
Page: 660-665
PDF size: 87.10 Kb.

ABSTRACT

Since the end of the XVIII century, digitalis glycosides were employed in heart failure. They were considered initially as diuretics and later as cardiotonic agents or as positive inotropics. At the present time there are varied groups of positive inotropic agents, which have a beneficial action on the failing human myocardium. For example, the beta adrenergics, the phosphodiesterase III inhibitors such as milrinone, or the sensibilizers of myocardial proteins to Ca++ such as levosimendan and omecamtiv mecarbil. However, following the opinion of distinguished cardiologists, in the case of heart failure associated to atrial fibrillation, digitalis cannot be substituted.

REFERENCES

1. Fuchsio L. De Historia stirpium. Basileae, in Oficina Isingriniana. 1542 ss.

2. Laín Entralgo P. Historia de la Medicina. Barcelona: Salvat Ed. S.A.; 1978. p. 259.

3. Fuchsio L. Neu Kräuterbuch. Basilea: Tip. Isingrin; 1543.

4. Lévy A. [The therapeutic advent of the irreplaceable leaf of Digitalis purpurea]. Coeur Med Interne. 1978;17(1):133-7.

5. Bock H. En Stenius: Die nuere geshichte der Digitalis purpurea and inre bedeutung in der Medizin. Arch wiss prakt Tierheibk. 1918,N05/6:44.

6. de Micheli-Serra A. [Digitalic therapy. Historical outline]. Gac Med Mex. 2000;136(5):511-8.

7. Withering W. An account of the foxglove and some of its medical use. Londres: G G J & J Robinson; 1785. Reproducción por la Society of Medical Classics, 1979.

8. Nativelle CL. Sur la digitaline cristallisée. J Pharm Chim. 1869;9:255 ss.

9. Schmiedeberg O. Uber die Digitaliswirkung am herzmuskel der frosches. Beir Anat Physiol. 1874;222 ss.

10. Houghton EM. The pharmacologic essay of the heart tonics. JAMA. 1898;31:959 ss.

11. Kraft K. Die glycoside der blätter der Digitalis purpurea. Arch Pharm. 1912;250:118 ss.

12. Stoll A. The cardiac glycosides. Londres: The Pharmacological Press; 1937.

13. Fleser LF, Fleser M. Steroid. Nueva York: Reinhold Publishing Co; 1959.

14. Edens E. A.B.C. de la medication digitalique. Lausana: Ed. Payot & Cie.; 1938.

15. Fraser TR. On the Kombè Arrow-Poison (Strophanthus Hispidus, D. C.) of Africa. J Anat Physiol. 1872;7(Pt 1):139-55.

16. Arnaud. Sur la composition élementaire de la strophantine cristallisée extraite du Strophantus Kombé. C.R. Acad Sci. 1888,107:179 SS.

17. Fraenkel A. Uber intravenöse Strophantin Therapie. Verh Dtsch Ges Inn Med. 1906:257 ss.

18. Kottmann K. Klinische Uber Digitoxinum Solubile Cloetta (Digalen). Z Klin Med. 1906;56:128 ss.

19. Méndez R. [200 years of digitalis]. Arch Inst Cardiol Mex. 1986;56(4):339-48.

20. Bidault de Williers FT. Essai sur les propiétés medicinales de la digitale pourpre. París; 1805.

21. Corvisart JN. Essai sur les maladies et les lésions organiques du coeur et des gros vaisseaux. París: Tip. Migneret; 1806. p. 415-33.

22. Laënnec RTH. Traité de l`auscultation mediate et des maladies du poumon et du coeur. París: Tip. J. S. Chaudé; 1826. T II. p. 735.

23. Bouillaud J. Traité clinique des maladies du coeur. París: E.J.B. Baillière; 1835. T. II. p. 461-2.

24. Alcántara Herrera J. Pequeño aporte cronológico y bibliográfico para escribir la historia de la cardiología en México. Medicina (Mex). 1949;29(576):101-17.

25. Carrillo M. Diagnóstico diferencial de las enfermedades del corazón. (tesis). México: Impr. del Comercio; 1870.

26. Icaza y Peza JR. Algunas consideraciones acerca de la acción fisiológica de la digital y las indicaciones de su empleo en las afecciones orgánicas del corazón. (tesis). México: Escuela Nacional de Medicina; 1872.

27. Chávez Sánchez I. La digitalina a pequeñas dosis en el tratamiento de las cardiopatías (tesis de la Facultad de Medicina). México: Universidad Nacional de México; 1920.

28. Fernández del Castillo F. Estudio histórico del Instituto Médico Nacional. México: Ed. UNAM; 1961.

29. Catálogo de tesis de medicina del siglo XIX. México; Ed. UNAM; 1988. p. 52.

30. Von Haller A. Mémoires sur les parties sensibles et irritables. 3 vols. Lausana: Tip. de Sigismond d`Arnay; 1760.

31. Marey EJ. Des excitations électriques du coeur. En: Marey M. Travaux du laboratoire. V ii. París: Ed. J. Masson; 1876. II. p. 63-86.

32. Vulpian EFA. Gaz Med Paris, 1855:599 (citado por Cushny, ref. n.o 40).

33. Cushny AR. The action and uses in medicine of digitalis and its allies. Londres: Longmans, Green & Co.; 1925.

34. Rosenblueth A, Alanís J, Mandoki J. The functional refractory period of axons. J Cell Comp Physiol. 1949;33(3):405-40.

35. Mendez R, Mandoki JJ, Méndez C. The functional refractory period of the atrium and ventricle of the mammalian heart. Memorias del 1.er Congreso Mundial de Cardiología, París. 1950;1:607.

36. Mendez R, Méndez C. The action of cardiac glycosides on the refractory period of heart tissues. J Pharmacol Exp Ther. 1953;107(1):24-36.

37. Méndez C, Aceves J, Mendez R. The antiadrenergic action of digitalis in the refractory period of the A-V transmission system. J Pharmacol Exp Ther. 1961;131:199-204.

38. Méndez C, Aceves J, Mendez R. Inhibition of adrenergic cardiac acceleration by cardiac glycosides. J Pharmacol Exp Ther. 1961;131:191-8.

39. Pastelín G, de Micheli A, Valadez F, Mendez R. [Antagonistic and additive effects of propranolol with digitalics]. Arch Inst Cardiol Mex. 1967;37(2):221-35.

40. Alvarado Acosta JL, Suárez Munguía J, Gutiérrez Perucho E, Martínez Morales F, Sánchez Sevilla L, Pastelin G. Un nuevo aspecto del mecanismo de acción de la ouabaína. En: Sánchez Torres G, Medrano GA, Pastelín G, editores. Farmacología cardiovascular. Nuevos principios en la patología de siempre. México: Ed. Piensa S.A.; 1992. p. 3-17.

41. Alvarado JL, Suárez J, Yahuaca P, Pastelín G. [The role of adenosine on the anti-arrhythmic action of digitalis glycosides]. Arch Inst Cardiol Mex. 1998;68(2):101-12.

42. Ramirez-Ortega M, Maldonado-Lagunas V, Melendez-Zajgla J, et al. Proliferation and apoptosis of hela cells induced by in vitro stimulation with digitalis. Eur J Pharmacol. 2006;534(1-3):71-6.

43. Khan MI, Chesney JA, Laber DA, Miller DM. Digitalis, a targeted therapy for cancer? Am J Med Sci. 2009;337(5):355-9.

44. Cerella C, Dicato M, Diederich M. Assembling the puzzle of anti-cancer mechanisms triggered by cardiac glycosides. Mitochondrion. 2013; 13(3):225-34.

45. Mendez R, Pastelín G, Kabela E. The influence of the position of attachment of the lactone ring to the steroid nucleous on the action of Cardiac glycosides. J Pharmacol Exp Ther. 1974;188(1):189-97.

46. Pastelin G, Mendez R. Singular effects of a new short acting cardiac glycoside in Purkinje cells. Eur J Pharmacol. 1972;19(2):291-3.

47. Castañeda-Hernández G. [The evidence for the existence of an endogenous factor with digitalis activity in mammals: a physiological regulator of the sodium pump?]. Arch Inst Cardiol Mex. 1991;61(5): 491-500.

48. Schoner W. Endogenous digitalis-like factors. Trends Pharmacol Sci. 1991;12(6):209-11.

49. Schoner W, Georgios SB. Endogenous and exogenous cardiac glycosides: their roles in hypertension,salt metabolism and cell grouth. Am J Physiol Cell Physiol. 2007;293(2):C509-36.

50. Wenger TL, Butler VP, Haber E, Smith TW. Treatment of 63 severely digitalis toxic patients with digoxin-specific antibody fragments. J Am Coll Cardiol. 1985;5(5 Suppl A):118A-123A.

51. Pastelín G, Mendez R, Kabela E, Farah A. The search for a digitalis substitute. II Milrinone (WIN-47203), its action on the heart-lung preparation of the dog. Life Sci. 1983;33(18):1787-96.

52. Farah AE, Alousi AA, Schwarz RP. Positive inotropic agents. Annu Rev Pharmacol Toxicol. 1984;24:275-328.

53. Sato N, Uechi M, Asai K, Patrick T, Kudej RK, Vatner SF. Effects of a novel inotropic agent, Bay 5959, in conscious dogs: comparison with dobutamina and milrinone. Am J Physiol. 1997;272(2 Pt 2):H753-9.

54. Packer M, Georghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-enzyme inhibitors. N Engl J Med. 1993;329(1):1-17.